Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Halozyme's Q3 Sales Soar

Halozyme (NASDAQ: HALO  ) sales jumped 200% this quarter, coming in at $16 million compared to Q3 2012's $5.3 million, according to results the company released today. The biopharmaceutical company's success was largely attributed to $7.9 million in sales of products including Halozyme's proprietary treatment ingredient, recombinant human hyaluronidase (rHuPH20), as well as $3.7 million paid from collaborators for research services reimbursements.

The quarter also saw growth in its profit margins, but not nearly on the same scale as its revenue. Halozyme's operating loss narrowed 7%, to $18.4 million, while its net loss shrunk 3% to $19.3 million. On the balance sheet, Halozyme's cash, cash equivalents, and marketable securities were $65.3 million at Sept. 30, 2013, compared with $76.0 million at June 30, 2013 and $99.5 million at December 31, 2012

In a statement, Halozyme CEO and President Gregory Frost said the last quarter was "remarkable" for Halozyme's European commercial launches of HyQvia and Herceptin SC, "each leveraging Halozyme's proprietary rHuPH20 technology to deliver more efficient treatment options." Frost also noted that data are emerging within the company's development programs "supporting the hypothesis that patients with high hyaluronan tumor levels may benefit most from PEGPH20 therapy in the treatment of pancreatic cancer." 

Editor's note: This story has been updated to reflect Halozyme's cash, cash equivalents, and marketable securities figures, and the headline has been updated.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 08, 2013, at 1:09 PM, stillwater9999 wrote:

    You did not comment on the news that Pfizer is advancing its programs with HALO. That would appear to be the news driving today's stock price rise.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2719085, ~/Articles/ArticleHandler.aspx, 9/27/2016 8:36:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
HALO $12.51 Up +0.53 +4.42%
Halozyme Therapeut… CAPS Rating: ***